{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-220638","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2026-05-13T12:00:44+00:00","discovered_at":"2026-05-13T12:05:00.408543+00:00","generated_at":"2026-05-13T12:08:55.935987+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tyra Biosciences Q1 net loss $39.3M; cash $383.5M; SURF302 data August 2026","bullets":["Net loss $39.3M vs $28.1M YoY; R&D expenses $33.5M (+34%) driven by dabogratinib trials.","Cash, equivalents & marketable securities $383.5M; runway into 2H 2028.","First patient dosed in LG-UTUC trial SURF303 (pivotal); initial results expected 2027.","Initial SURF302 data (IR NMIBC) due August 2026; BEACH301 safety sentinel data Q4 2026.","Appointed Habib Dable to Board; raised $147.9M net via ATM in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-220638","json":"https://secwatch.observer/filing/0001193125-26-220638.json","markdown":"https://secwatch.observer/filing/0001193125-26-220638.md","text":"https://secwatch.observer/filing/0001193125-26-220638.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/0001193125-26-220638-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/tyra-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:08:55.935987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76d0799f11faeb637f76b4ed7778685e8aa488dc","claim":"Tyra Biosciences, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 13, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/0001193125-26-220638-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}